Abstract 46P
Background
MicroRNAs (miRNAs), small non-coding RNAs that influence gene expression, have shown promising potential as biomarkers for cancer detection due to their stability and detectability in bodily fluids. Specifically, microRNA-1246 (miR-1246) has been preliminarily suggested to be effective in early-stage breast cancer detection, warranting an exhaustive analysis to verify its reliability and applicability as a non-invasive diagnostic indicator. The study aims to determine the accuracy of miR-1246 as a biomarker for the early detection of breast cancer.
Methods
A comprehensive search of databases, including PubMed, Embase, and the Cochrane Library, was conducted for studies published up to May 2023. Inclusion criteria were studies exploring the diagnostic efficacy of miR-1246 in early-stage breast cancer detection, with healthy individuals serving as a control group. Statistical analyses were performed using R software (version 4.0.3) with the mada package, which facilitated the pooling of sensitivity, specificity, false-positive rate estimates, diagnostic odds ratio, and both positive and negative Likelihood Ratios (LR), each with a 95% Confidence Interval (CI).
Results
Our meta-analysis consisted of 5 studies involving 3041 participants, with 1489 patients diagnosed with breast cancer and 1552 healthy controls. miR-1246 showed considerable diagnostic potential for early-stage breast cancer detection, exhibiting a sensitivity of 87.1% (95% CI: 76.9-93.2%, I2=78.6%) and a specificity of 89.4% (95% CI: 81.6-94.1%, I2=82%). The diagnostic odds ratio (DOR) was 57.05 (95% CI: 21.91-148.54), and the false-positive rate was 10.6% (95% CI: 5.9-18.4%). Additionally, Likelihood Ratios (LR) indicated a positive LR of 8.23 (95% CI: 4.59-14.75) and a negative LR of 0.14 (95% CI: 0.08-0.27).
Conclusions
The study highlights the promising potential of miR-1246 as a non-invasive biomarker for early breast cancer detection, though the observed heterogeneity across studies underscores the need for further comprehensive research. If validated with further studies, the integration of miR-1246 into existing diagnostic methods could significantly enhance early detection and improve patient prognosis.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
63P - The impact of disruption of melatonin secretion on the structural-functional changes of the microbiome and the role of the melatonin-microbiome axis in the initiation of carcinogenesis
Presenter: Alexandre Tavartkiladze
Session: Cocktail & Poster Display session
Resources:
Abstract
64P - Acidosis induces ferroptosis of breast cancer via ZFAND5/SLC3A2 axis with the synergistic effect of metformin and facilitates M1 macrophage polarization
Presenter: Hanchu Xiong
Session: Cocktail & Poster Display session
Resources:
Abstract
65P - Transmembrane distribution of phosphatidylethanolamine in plasma membrane of ovarian cancer cells under conditions mimicking tumor microenvironment
Presenter: Darya Savenkova
Session: Cocktail & Poster Display session
Resources:
Abstract
66P - Metabolic regulation of GMP- and MDP-derived macrophages in glioblastoma
Presenter: Liam Wilson
Session: Cocktail & Poster Display session
Resources:
Abstract
67P - Inflammation status and sarcopenia synergistically impact outcomes in cancer patients (pt) treated with ImmunOtherapy (IO) within the framework of a Molecular Pre-screening program (MP) and a spEcial Medication (ME) program
Presenter: Lucia Notario Rincon
Session: Cocktail & Poster Display session
Resources:
Abstract
68P - The role of systemic reprogramming of GMPs in improving outcomes in glioblastoma
Presenter: Aline Atallah
Session: Cocktail & Poster Display session
Resources:
Abstract
69P - Integrated OMIC analysis reveals arginine and proline metabolism plays critical role in hypoxia-induced oral squamous cell carcinoma
Presenter: Avinash Singh
Session: Cocktail & Poster Display session
Resources:
Abstract
70P - Individualising methotrexate dose based on MTHFR gene polymorphisms in acute lymphoblastic leukemia
Presenter: Meher Konatam
Session: Cocktail & Poster Display session
Resources:
Abstract
71P - Single nucleotide polymorphisms in the folate metabolic pathway genes and global DNA methylation in ovarian cancer
Presenter: Sandro Surmava
Session: Cocktail & Poster Display session
Resources:
Abstract
72P - Role of pyruvate carboxykinase 2 upregulation in group 3 medulloblastoma: Implications for metabolic reprogramming and therapeutic strategies
Presenter: MEDHA GAYATHRI PAI
Session: Cocktail & Poster Display session
Resources:
Abstract